Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Stock Price & Analysis

2 Followers

0719 Stock Chart & Stats

HK$5.36-HK$0.06(-1.20%)
At close: 4:00 PM GMT+8
HK$5.5HK$6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 5.36 - HKD 5.42
52-Week Range
HKD 5.18 - HKD 7.64
Previous Close
HKD 5.42
Volume
N/A
Average Volume (3M)
322.76K
Market Cap
HKD 8.52B
Enterprise Value
HKD 4.99B
Total Cash (Recent Filing)
HKD 1.19B
Total Debt (Recent Filing)
HKD 1.23B
Price to Earnings (P/E)
38.5
Beta
0.59
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
0.42
Last Dividend Ex-Date
Jul 10, 2026
Dividend Yield
3.18%

Bulls Say, Bears Say

Bulls Say

Manageable Leverage

The company remains profitable while debt-to-equity has generally stayed near 0.24–0.34, indicating leverage is manageable. A growing equity base provides financial capacity to sustain operations and pursue investment through the next several quarters.

Positive Cash Generation

Positive operating and free cash flow, together with strong TTM conversion of earnings into cash, supports internally funded operations. This improves financial resilience and gives the company greater flexibility to maintain investment and meet obligations over the medium term.

Integrated Pharmaceutical Platform

Operating across APIs, finished dosage forms, manufacturing, and commercial distribution gives the company a broad pharmaceutical platform. Serving both domestic and international markets can support diversified revenue channels and deepen its established industry position.

Bears Say

Revenue Slowdown

The TTM revenue pullback interrupts the company’s prior multi-year growth pattern and signals weaker recent demand or business momentum. If sustained, slower sales would reduce operating leverage and make it harder to rebuild earnings growth over the next several quarters.

Margin Compression

Sharp gross- and net-margin compression has reduced the profit generated from each unit of revenue. This weakens earnings resilience, limits reinvestment capacity, and leaves future profitability more dependent on recovering margins rather than growth alone.

Uneven Free Cash Flow

Although current cash generation is positive, the decline in TTM free cash flow and history of volatility make cash conversion less dependable. Uneven internally generated cash can constrain capital allocation and reduce flexibility if weaker profitability persists.

Shandong Xinhua Pharmaceutical Company Limited Class H News

0719 FAQ

What was Shandong Xinhua Pharmaceutical Company Limited Class H’s price range in the past 12 months?
Shandong Xinhua Pharmaceutical Company Limited Class H lowest stock price was HK$5.18 and its highest was HK$7.64 in the past 12 months.
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap?
Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap is HK$8.52B.
When is Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date?
Shandong Xinhua Pharmaceutical Company Limited Class H’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 139 days.
How were Shandong Xinhua Pharmaceutical Company Limited Class H’s earnings last quarter?
Shandong Xinhua Pharmaceutical Company Limited Class H released its earnings results on Oct 28, 2026. The company reported HK$0.141 earnings per share for the quarter.
Is Shandong Xinhua Pharmaceutical Company Limited Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Shandong Xinhua Pharmaceutical Company Limited Class H pay dividends?
Shandong Xinhua Pharmaceutical Company Limited Class H pays an annual dividend of HK$0.172 which represents an annual dividend yield of 3.18%. See more information on Shandong Xinhua Pharmaceutical Company Limited Class H dividends here
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate?
Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate is 0.42.
How many shares outstanding does Shandong Xinhua Pharmaceutical Company Limited Class H have?
Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding.
What happened to Shandong Xinhua Pharmaceutical Company Limited Class H’s price movement after its last earnings report?
Shandong Xinhua Pharmaceutical Company Limited Class H reported an EPS of HK$0.141 in its last earnings report. Following the earnings report the stock price went up 1.399%.
Which hedge fund is a major shareholder of Shandong Xinhua Pharmaceutical Company Limited Class H?
Currently, no hedge funds are holding shares in HK:0719
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology